Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 23511926)

1.

Ascites metabolism measurement enhanced the diagnostic value and accuracy of prognostic evaluation in 18F-FDG PET/CT studies in malignant ascites patients.

Li XJ, Li FQ, Han JK, Zhao ZH, Song ZG, Dai XZ.

Nucl Med Commun. 2013 Jun;34(6):544-50. doi: 10.1097/MNM.0b013e32836066f0.

PMID:
23511926
2.

The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.

Zhang M, Jiang X, Zhang M, Xu H, Zhai G, Li B.

J Nucl Med. 2009 Apr;50(4):506-12. doi: 10.2967/jnumed.108.056382. Epub 2009 Mar 16.

3.
4.

Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.

Santhosh S, Mittal BR, Bhasin D, Srinivasan R, Rana S, Das A, Nada R, Bhattacharya A, Gupta R, Kapoor R.

J Gastroenterol Hepatol. 2013 Feb;28(2):255-61. doi: 10.1111/jgh.12068.

PMID:
23278193
5.

Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.

Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, Kuwabara M, Yagyu Y, Kumano S, Imaoka I, Tsuchiya N, Ashikaga R, Hosono M, Murakami T.

Ann Nucl Med. 2009 Jun;23(4):349-54. doi: 10.1007/s12149-009-0246-4. Epub 2009 Apr 2.

PMID:
19340526
6.

[Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].

Xu XX, Cheng J, Xu WG, Dai D, Song XY, Ma WC, Zhu L, Zhu X.

Zhonghua Zhong Liu Za Zhi. 2012 May;34(5):364-8. doi: 10. 3760/cma.j.issn.0253-3766.2012.05.010. Chinese.

PMID:
22883458
8.

Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.

Palomar A, Nanni C, Castellucci P, Ambrosini V, Montini GC, Allegri V, Pettinato C, Al-Nahhas A, Soriano A, Grassetto G, Rubello D, Fanti S.

Mol Imaging Biol. 2012 Feb;14(1):123-9. doi: 10.1007/s11307-010-0468-9.

PMID:
21240639
9.

Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?

Mirpour S, Meteesatien P, Khandani AH.

Rev Esp Med Nucl Imagen Mol. 2012 Mar-Apr;31(2):71-7. doi: 10.1016/j.remn.2011.05.006. Epub 2011 Nov 16.

PMID:
22088805
10.

The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.

Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH.

Ann Nucl Med. 2008 Aug;22(7):603-9. doi: 10.1007/s12149-008-0151-2. Epub 2008 Aug 29.

PMID:
18756363
11.

Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Shin DS, Shon OJ, Byun SJ, Choi JH, Chun KA, Cho IH.

Skeletal Radiol. 2008 May;37(5):415-21. doi: 10.1007/s00256-008-0462-3. Epub 2008 Feb 29.

PMID:
18309481
12.

Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.

Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, Pane F, Salvatore M, Pace L.

J Nucl Med. 2012 Dec;53(12):1829-35. doi: 10.2967/jnumed.112.106500. Epub 2012 Oct 15.

13.

Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.

Guan ZW, Xu BX, Wang RM, Sun L, Tian JH.

Hell J Nucl Med. 2013 May-Aug;16(2):97-102. doi: 10.1967/s002449910084. Epub 2013 May 20. Review.

14.
15.

Supraclavicular lymph nodes detected by 18F-FDG PET/CT in cancer patients: assessment with 18F-FDG PET/CT and sonography.

Lee JH, Kim J, Moon HJ, Cho A, Yun M, Lee JD, Kang WJ.

AJR Am J Roentgenol. 2012 Jan;198(1):187-93. doi: 10.2214/AJR.11.6999.

PMID:
22194496
16.

Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.

Hu SL, Yang ZY, Zhou ZR, Yu XJ, Ping B, Zhang YJ.

Nucl Med Commun. 2013 Jun;34(6):533-9. doi: 10.1097/MNM.0b013e328360668a.

PMID:
23503000
17.

Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.

Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, Uematsu K, Sakai H, Goya T, Kanazawa M, Machida K.

Oncol Rep. 2012 Feb;27(2):333-8. doi: 10.3892/or.2011.1520. Epub 2011 Oct 24.

PMID:
22024889
18.

18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.

Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM.

J Nucl Med. 2013 Oct;54(10):1710-6. doi: 10.2967/jnumed.112.119370. Epub 2013 Aug 22.

19.

Whole-body MR-DWIBS vs. [18F]-FDG-PET/CT in the study of malignant tumors: a retrospective study.

Cafagna D, Rubini G, Iuele F, Maggialetti N, Notaristefano A, Pinto D, Niccoli-Asabella A, Palmiotti G, Lasciarrea M, Maggialetti A.

Radiol Med. 2012 Mar;117(2):293-311. doi: 10.1007/s11547-011-0708-3. Epub 2011 Jul 9.

PMID:
21744252
20.

Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.

Cheng NM, Fang YH, Chang JT, Huang CG, Tsan DL, Ng SH, Wang HM, Lin CY, Liao CT, Yen TC.

J Nucl Med. 2013 Oct;54(10):1703-9. doi: 10.2967/jnumed.112.119289. Epub 2013 Sep 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk